Cargando…
Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease
Parkinson’ disease (PD) is the second most prevalent neurodegenerative disease worldwide. To date, there is no disease-modifying agent, and current medical treatment only provides symptomatic benefits. Early diagnosis of PD would be useful in clinical practice to identify patients for clinical trial...
Autores principales: | Santiago, Jose A., Potashkin, Judith A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665557/ https://www.ncbi.nlm.nih.gov/pubmed/26852683 http://dx.doi.org/10.3390/diagnostics4040153 |
Ejemplares similares
-
Evaluation of RNA Blood Biomarkers in the Parkinson’s Disease Biomarkers Program
por: Santiago, Jose A., et al.
Publicado: (2018) -
Blood Transcriptomic Meta-analysis Identifies Dysregulation of Hemoglobin and Iron Metabolism in Parkinson’ Disease
por: Santiago, Jose A., et al.
Publicado: (2017) -
Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson’s Disease Patients
por: Santiago, Jose A., et al.
Publicado: (2015) -
Integrative transcriptomic meta-analysis of Parkinson’s disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson’s disease
por: Santiago, Jose A., et al.
Publicado: (2016) -
Biological and Clinical Implications of Comorbidities in Parkinson’s Disease
por: Santiago, Jose A., et al.
Publicado: (2017)